PureTech Health plc (OTCMKTS:PTCHF – Get Free Report) shares traded down 0.7% during trading on Friday . The company traded as low as $2.12 and last traded at $2.12. 10,100 shares were traded during trading, a decline of 69% from the average session volume of 33,049 shares. The stock had previously closed at $2.13.
PureTech Health Trading Down 0.7 %
The business’s 50-day moving average price is $1.94 and its 200 day moving average price is $2.26.
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Featured Articles
- Five stocks we like better than PureTech Health
- What Are Some of the Best Large-Cap Stocks to Buy?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Comparing and Trading High PE Ratio Stocks
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- How to Read Stock Charts for Beginners
- Time to Load Up on Home Builders?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
